Phospholipase A2 inhibitors in atherosclerosis: the race is on

The Lancet

Volumn 373, Issue 9664, 2009, Pages 608-610

  Corson, Marshall A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H INDOLE 3 GLYOXAMIDE; A 002; ATORVASTATIN; C REACTIVE PROTEIN; DARAPLADIB; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2 INHIBITOR; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; BENZALDEHYDE DERIVATIVE; ENZYME INHIBITOR; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIME; PYRROLE DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; DRUG EFFICACY; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLOOD; CLASSIFICATION; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; ENZYMOLOGY; NOTE; PHASE 2 CLINICAL TRIAL;

BENZALDEHYDES; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE II AS TOPIC; CORONARY ARTERY DISEASE; CORONARY DISEASE; ENZYME INHIBITORS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIMES; PHOSPHOLIPASES A2, SECRETORY; PYRROLES;

EID: 60249083241     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60378-0     Document Type: Note

References (14)

1. Schaloske R.H., and Dennis E.A. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 1761 (2006) 1246-1259
2. Mallat Z., Benessiano J., Simon T., et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 27 (2007) 1177-1183
3. Crandall M.A., and Corson M.A. Use of biomarkers to develop treatment strategies for atherosclerosis. Curr Treat Options Cardiovasc Med 10 (2008) 304-315
4. Wilensky R.L., Shi Y., Mohler E.R., et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 14 (2008) 1059-1066
5. Menschikowski M., Hagelgans A., and Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. Prostaglandins Other Lipid Mediat 79 (2006) 1-33
6. Lavi S., McConnell J.P., Rihal C.S., et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115 (2007) 2715-2721
7. Kolodgie F.D., Burke A.P., Skorija K.S., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 2523-2529
8. Jonsson-Rylander A.C., Lundin S., Rosengren B., Pettersson C., and Hurt-Camejo E. Role of secretory phospholipases in atherogenesis. Curr Atheroscler Rep 10 (2008) 252-259
9. 2 (PLASMA Study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 373 (2009) 649-658
10. ClinicalTrials.gov. FRANCIS-ACS trial: a study of the safety and efficacy of A 002 in subjects with acute coronary syndromes. 2008. http://clinicaltrials.gov/ct2/show/NCT00743925 (accessed Oct 20, 2008).
11. Mohler E.R., Ballantyne C.M., Davidson M.H., et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 51 (2008) 1632-1641
12. Serruys P.W., Garcia-Garcia H.M., Buszman P., et al., on behalf of the Integrated Biomarker and Imaging study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118 (2008) 1172-1182
13. ClinicalTrials.gov. The stabilization of atherosclerotic plaque by initiation of darapladib therapy trial (STABILITY). 2008. http://clinicaltrials.gov/ct2/show/NCT00799903 (accessed Dec 15, 2008).
14. Tardif J.C., McMurray J.J., Klug E., et al., on behalf of the Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008) 1761-1768